← Leaderboards
Shahab Asgharzadeh
Children'S Hosp Of Philadelphia
$4,442,796
Attributed
$9,991,903
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,991,903 · 4
By mechanism
U01$5,678,350 · 1
R01$3,527,081 · 2
P01$786,472 · 1
Top collaborators
- Robert C Seeger3 shared
- James F Amatruda2 shared
- Long Cai2 shared
- Muller Fabbri2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Julie R Park$6,704,912
- John M Maris$30,818,378
- Crystal Mackall$19,988,621
- Jessica B Foster$905,375
- Robbie G. Majzner$6,350,674
Others in their field
Top investigators on “Neuroblastoma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Gregory H Reaman · National Childhood Cancer Foundation$84,462,747
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$58,436,699
- Larry Arthur$30,516,306
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
NeuroblastomaMalignant NeoplasmsHigh RiskTumorChemotherapyNeoplastic CellNeuroblastoma CellResponseBiologySamplingChildGenesMediatingCellsTumor MicroenvironmentResistanceTransforming Growth Factor BetaPathway InteractionsProteinsImmunotherapyRelapseMycn GeneDiagnosisLos Angeles
Grant awards (9)
Pediatric Solid Tumor Microenvironment Atlas$4,528,480
U01 · FY2025 · CA · contact PI
Clinical Implications of Natural Killer-derived exosomal miRNAs in Neuroblastoma$732,471
R01 · FY2025 · CA
Tumor microenvironment-dependent therapy resistance$407,872
P01 · FY2025 · CA · contact PI
Pediatric Solid Tumor Microenvironment Atlas$1,149,870
U01 · FY2024 · CA · contact PI
Clinical Implications of Natural Killer-derived exosomal miRNAs in Neuroblastoma$752,969
R01 · FY2024 · CA
Tumor microenvironment-dependent therapy resistance$378,600
P01 · FY2024 · CA · contact PI
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$665,155
R01 · FY2016 · CA · contact PI
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$671,686
R01 · FY2015 · CA · contact PI
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma$704,800
R01 · FY2014 · CA · contact PI